Structure Therapeutics Quarterly Income Statement
NASDAQ: GPCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
25.54-0.13 (-0.51%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Structure Therapeutics revenue and earnings
Structure Therapeutics reported a net loss of $106.2 million, compared with a loss of $61.7 million a year earlier. Diluted earnings per share came in at -$0.49.
Summary generated from market data by MetaCap's automated system. Methodology
Structure Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 118.63M | 89.38M | -23.99M | 73.79M | 70.45M | 56.31M | 47.06M | 45.84M | 33.32M | 32.02M | 30.99M | 26.14M |
| Research & Development | 100.06M | 66.51M | 68.69M | 58.99M | 54.71M | 42.87M | 33.49M | 32.60M | 22.05M | 20.68M | 20.04M | 17.52M |
| Operating Income | -118.63M | -89.38M | 23.99M | -73.79M | -70.45M | -56.31M | -47.06M | -45.84M | -33.32M | -32.02M | -30.99M | -26.14M |
| Pretax Income | -105.92M | -75.78M | 33.17M | -65.60M | -61.52M | -46.73M | -36.34M | -33.88M | -25.98M | -26.01M | -24.82M | -23.46M |
| Income Tax | 234.00K | 190.00K | 170.00K | 108.00K | 139.00K | 98.00K | 136.00K | 92.00K | 53.00K | 29.00K | -312.00K | 405.00K |
| Net Income | -106.16M | -75.97M | 33.00M | -65.71M | -61.66M | -46.83M | -36.48M | -33.98M | -26.03M | -26.04M | -24.50M | -23.86M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.49 | -0.35 | 0.20 | -0.37 | -0.36 | -0.27 | -0.21 | -0.20 | -0.18 | -0.19 | -0.15 | -0.21 |
| EPS (Diluted) | -0.49 | -0.35 | 0.20 | -0.37 | -0.36 | -0.27 | -0.21 | -0.20 | -0.18 | -0.19 | -0.15 | -0.21 |
| Shares Outstanding (Basic) | 217.96M | 217.33M | — | 175.47M | 172.65M | 172.05M | — | 171.63M | 148.24M | 139.71M | — | 114.95M |
| Shares Outstanding (Diluted) | 217.96M | 217.33M | — | 175.47M | 172.65M | 172.05M | — | 171.63M | 148.24M | 139.71M | — | 114.95M |
| EBITDA | -118.08M | -88.80M | 24.40M | -73.43M | -70.16M | -56.04M | -46.79M | -45.57M | -33.08M | -31.79M | -30.92M | -26.07M |
This table shows 12 quarterly periods of Structure Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow GPCR's reporting calendar. What is a income statement?